QLQu Lin

Qu Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qu Lin has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Xiang-Yuan Wu

    Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    15 shared publications
  • Xing Li

    Department of Medical Oncology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

    12 shared publications
  • Min Dong

    Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, People's Republic of China

    10 shared publications
  • Xiao-Kun Ma

    Department of Medical Oncology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

    9 shared publications
  • Zhan-Hong Chen

    Department of Medical Oncology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    9 shared publications
  • Jing-Yun Wen

    8 shared publications

Latest Publications

  • Open Access

    Complete Response With Cetuximab-Based Treatment of Metastatic Colorectal Cancers: Two Case Reports and Literature Review

    by Li Wei, Zexiao Lin, Sidong Xie, Danyun Ruan, Wen Jiang, Yueli Cui, Sisi Liu, Tiantian Wang, Zhanhong Chen, Qu Lin

    Metastases typically develop before diagnosis and during the treatment of colorectal cancers, while patients with metastatic colorectal cancers (mCRCs) currently have a poor prognosis. In terms of surgical approaches, adjuvant therapies, and targeted therapies, the treatment of mCRCs has had numerous recent advances. As a targeted agent widely used in mCRCs, cetuximab-based treatment is still under dispute due to its side effects and unstable effect. We present two mCRC cases treated with cetuximab-based therapy, of which two patients achieved complete response and without recurrence for over 22 and 84 months, respectively. To better understand the drug usage, we also reviewed the recent achievements and usage precautions of cetuximab in mCRCs. Present and many previous observations support that cetuximab might be a referred drug in the first-line chemotherapy of mCRCs with wild-type RAS and BRAF and proficient mismatch repair.


  • Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma

    by Zhi-Huan Lin, Jun-Rong Jiang, Xiao-Kun Ma, Jie Chen, He-Ping Li, Xing Li, Xiang-Yuan Wu, Ming-Sheng Huang, Qu Lin

    Transarterial chemoembolization (TACE) induces a change in serum HIF-1α level in patients with hepatocellular carcinoma (HCC). This study investigated the prognostic value of change in serum HIF-1α following TACE treatment in HCC patients. A total of 61 hepatocellular carcinoma patients treated with TACE were included. Peripheral blood samples were collected within 1 week before and after TACE to determine the serum levels of hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor-A (VEGF-A) by enzyme-linked immunosorbent assay (ELISA). Serum HIF-1α change was calculated as follows: ∆HIF-1α = (HIF-1α (pre-TACE) − HIF-1α (post-TACE))/HIF-1α (pre-TACE). Likewise, serum VEG-F change was calculated as follows: ∆VEG-F = (VEG-F (pre-TACE) − VEG-F(post-TACE))/VEG-F (pre-TACE). Based on the cutoffs (0.25) determined by the maximum Youden’s index in receiver operating characteristic analysis, the patients were grouped into the low ∆HIF-1α group (< 0.25) and the high ∆HIF-1α group (> 0.25). After TACE treatment, HIF-1α was significantly decreased (pre-TACE 1901.62 vs. post-TACE 621.82 pg/ml, P < 0.01) but VEGF-A was significantly increased (pre-TACE 60.80 vs. post-TACE 143.81 pg/ml, P < 0.01). Multivariate logistic regression analysis demonstrated that ∆HIF-1α was a prognostic factor (OR = 58.09, 95% CI: 1.59–2127.32, P = 0.027) for the TACE treatment response. Furthermore, multivariate Cox regression analysis revealed that ∆HIF-1α was a prognostic factor for progression-free survival (PFS) (HR = 0.30, 95% CI: 0.14–0.66, P = 0.003) and overall survival (OS) (estimated HR = 0.38, 95% CI: 0.16–0.93, P = 0.034). Kaplan–Meier survival analysis showed that the high ∆HIF-1α group was more likely to have longer PFS (log-rank test, P = 0.004) and OS (log-rank test, P = 0.002) than the low ∆HIF-1α group. The change in serum HIF-1α level following TACE is a prognostic factor associated with the TACE treatment response, PFS, and OS in HCC patients following TACE.


  • A new prognostic model based on total tumor volume to predict survival rate in locally advanced hepatocellular carcinoma patients.

    by Zhan-Hong Chen, Jin-Xiang Lin, Qu Lin, Xing Li, Ying-Fen Hong, Xiang-Yuan Wu

    E15622 Background: Many HCC patients are diagnosed as locally advanced and loco-regional therapies improved the prognosis of these patients. Survival rates of these patients vary differently. We want to research on the prognostic factors and establish a new prognostic model based on total tumor volume(TTV) to predict the survival rate in locally advanced hepatocellular carcinoma patients who receive loco-regional therapy. Methods: 214 locally advanced HCC patients who received TACE or PEJ were retrospectively studied. Univariate and multivariate analyses were used to assess the variables. A new prognostic model based on TTV was developed with independent prognostic factors. The predictive value was evaluated using receiver operator characteristic curve (ROC) analyses. Results: The median survival is 23.4 months. Univariate and multivariate analyses showed that total tumor volume (TTV), child-pugh garde, protal vein thrombosis and antivirus therapy were independent factors of overall survival. A risk model was establsihed and it is consisted of 4 factors mentioned above. 214 patients were classified into 5 stages by the new staging system. We researched on the predictive value of the new prognostic system by comparing it with CLIP, BCLC and TNM. When predicting 1-year OS, AUC of the new prognostic system, CLIP, BCLC and TNM is 0.620, 0.735, 0.527 and 0.655, respectively; CLIP is best when predicting 1-year os. When predicting 2-year OS, AUC of the new prognostic system, CLIP, BCLC and TNM is 0.623, 0.671, 0.516 and 0.577, respectively;The new prognostic system is as good as CLIP. When predicting 3-year OS, AUC of the new prognostic system, CLIP, BCLC and TNM is 0.623, 0.645, 0.504 and 0.593, respectively; The new prognostic system is as good as CLIP and is better than BCLC(P < 0.05). Conclusions: Total tumor volume is independent prognotic factors of locally advanced hepatocellular carcinoma patients who received locoregional therapies.The new prognostic system based on TTV is as good as CLIP in predicting 2-year OS and 3-year OS. A new prognostic system based on TTV TTV(CM3) < 22.5(0) ≥22.5(1) Antivirus therapy No(0) Yes(1) Child pugh Grade A(0) B(1) Portal vein thrombosis No(0) Yes(1)

  • Prognostic significance of preoperative albumin-to-globulin ratio in patients with cholangiocarcinoma

    by Q. Lin, Z.-H. Lin, J. Chen, J.-X. Lin, X. Li, J.-R. Jiang, X.-K. Ma, D.-H. Wu, Z.-H. Chen, M. Dong, et al.


  • Open Access

    Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review

    by Xiu-Rong Cai, Xing Li, Jin-Xiang Lin, Tian-Tian Wang, Min Dong, Zhan-Hong Chen, Chang-Chang Jia, Ying-Fen Hong, Qu Lin, Xiang-Yuan Wu

    Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review


  • Comparison of a new prognostic system and six current staging systems in predicting the survival rate of patients with advanced hepatocellular carcinoma undergoing loco-regional therapy.

    by Ying-Fen Hong, Zhan-Hong Chen, Xing Li, Zhi-Huan Lin, Xiu-Rong Cai, Tian-Tian Wang, Chang-Chang Jia, Qu Lin, Mingsheng Huang, Xiang-Yuan Wu

    E15615 Background: Prognosis of patients with advanced HCC(aHCC) is very poor even though they receive loco-regional therapy. We have established a new prognostic system called SYSU system (variables are listed below) and now we want to compare this new prognostic system and 6 current staging systems in predicting the survival rate of patients with aHCC undergoing loco-regional therapy. Methods: A total of 220 aHCC patients undergoing loco-regional therapy were analyzed. The methods of loco-regional therapy included transarterial chemotherapy with or without concomitant embolization, percutaneous ethanol injection except radical surgery and systemic treatment. Data were collected to classify patients according to our new system (SYSU system), Cancer of the Liver Italian Program (CLIP), Chinese University Prognostic Index staging system for HCC (CUPI), Chinese integrated score (CIS), Child-Pugh Score and TNM staging system at diagnosis. 1-year OS, 2-year OS and OS were the end points used in the analysis. Results: The median survival is 21.2 months. When predicting 1-year OS, AUC of CLIP, SYSU, CIS, TNM, CUPI and CHILD is 0.739, 0.720, 0.661, 0.654, 0.625 and 0.553. When predicting 2-year OS, AUC of CLIP, SYSU, CIS, CUPI, TNM and CHILD is 0.676, 0.674, 0.617, 0.583, 0.578,and 0.566. AUCs of CLIP and SYSU share similar at predicting 1-year and 2-year OS ( both P>0.05) , and they are both significantly higher than the other five staging systems. When predicting OS, likelihood ratio test show χ2 of CLIP, SYSU, TNM, CIS, CUPI and CHILD is 29.3, 26.7, 16.7, 15.8, 14.2 and 6.0. AIC of CLIP, SYSU, TNM, CIS, CUPI, and CHILD is 1343.4, 1346.2, 1354.4, 1356.7,1358.4 and 1366.6.The CLIP system and our SYSU system both have best performance in terms of discriminatory ability, homogeneity and monotonicity. Conclusions: Our SYSU system and CLIP are the best score systems in prediction of 1-year OS, 2-year OS and OS among the 7 systems analyzed for Chinese aHCC patients undergoing loco-regional therapy.

  • Predictive value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) for patients with advanced HBV-associated HCC.

    by Zhan-Hong Chen, Jin-Xiang Lin, Ying-Fen Hong, Min Dong, Qu Lin, Xiang-Yuan Wu

    E15609 Background: Many researches indicate that cancer triggers a systemic inflammatory response, causing changes in circulating inflammatory cells. These inflammatory cells are important in the growth, maturation and differentiation of cells within tumour microenvironment. NLR, PLR, and LMR, have been found to be associated with the oncologic outcomes in renal, colorectal, breast and lung cancer. Few reports have focused on the prognostic value of NLR, PLR and LMR in patients with advanced HCC.We evaluated their predictive value. Methods: From September 2008 to June 2010, 174 patients with HBV-associated advanced HCC without fever or signs of infections were analyzed retrospectively. Patient demographics, tumor characteristics and prognostic scores results were recorded. Univariate and multivariate analyses were performed, using the Cox proportional hazards model. Receiver operating characteristics curves were used to determine prognostic score cutoffs. Results: Univariate analysis identified tumour size, portal vein thrombosis, BUN, WBC, monocyte, platelet, NLR, PLR and LMR as independent prognostic factor in Overall survival(OS) in patients with advanced HCC(P < 0.01 ). The multivariate analysis identified tumour size, portal vein thrombosis, BUN and PLR as independent prognostic factor (P < 0.01 ). The PLR cutoff was 90.5 and had the greatest area under the curve (AUC) of 0.705, followed by NLR(cutoff > 2.58; AUC, 0.605) and LMR (cutoff ≤ 4.52; AUC, 0.567).AUC of PLR had a tendency to be statistically significant than that of LMR(P = 0.0585). There did not exist statistical significance between AUC of PLR and NLR, NLR and LMR. Based on cutoff point of PLR, all patients were dichotomized into either a low PLR group( ≤ 90.5) or a high PLR group( > 90.5). OS of low PLR group was significantly longer than that of high PLR group(P < 0.01 ).Higher PLR level was significantly correlated with portal vein thrombosis and larger tumor size(P < 0.01). Conclusions: PLR may provide a simple, cost-effective and easily measured prognostic marker for advanced HCC patients. Lower Baseline PLR levels indicates better prognosis.

  • Platelet-to-hemoglobin ratio as a prognostic factor for hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization.

    by Xing Li, Zhi-Huan Lin, Ying-Fen Hong, Tian-Tian Wang, Dong-Hao Wu, Xiao-Kun Ma, Yan-Fang Xing, Mingsheng Huang, Min Dong, Qu Lin, et al.

    E15591 Background: The prognosis of hepatocellular carcinoma (HCC) patients receiving transcatheter arterial chemoembolization (TACE) is far from being identified. The present study aimed to assess role of blood cell counts, routine liver function tests in predicting the progression-free survival (PFS) of these patients. Methods: A total of 243 HCC patients receiving TACE were analyzed retrospectively. The current staging systems of HCC were investigated about their performance of prediction. And then, the novel prognostic factors were integrated in to the best staging systems to determine their independency. Results: Cancer of the Liver Italian Program (CLIP) score system and advanced liver cancer prognostic system (ALCPS) stages were indentified to be the best score systems among current 12 staging systems for this patient subgroup according akaike information criterion (AIC) index and linear trend χ2. Then, the novel prognostic value of parameters was determined by integration into CLIP and ALCPS score systems. As a result, Platelet-to-Hemoglobin Ratio (PHR) were confirmed to an independent predictor for PFS of HCC patients receiving TACE when integrated into CLIP, BCLC and ALCPS score systems (p= 0.026 and 0.009, respectively) with the other parameters, including platelet and hemoglobin, failed to reach statistical significance. Moreover,PHR improved the performance of CLIP, BCLC and ALCPS score systems by adjusted into it, thus improved the discriminatory ability. Furthermore, PHR were defined value ≤ 1.26 as low level and > 1.26 as high level, according to which patients were dichotomized into two groups. HCC patients receiving TACE with low PHR presented better 1 year disease progress rate (24.0% vs 41%) and overall survival (62.5% vs 38.8%) compared with patients with high PHR level. Besides, PHR level was associated with prognostic factors such as international normalized ratio, incidence of ascites, serum albumin, serum α-fetoprotein, total bilirubin and portal vein thrombosis. Conclusions: In summary, the present study firstly indentified PHR as an independent prognostic factor in HCC patients receiving TACE.


  • Serum albumin to globulin ratio as an indicator for the prognosis for cholangiocarcinoma.

    by Qu Lin, Zhi-Huan Lin, Jie Chen, Mingsheng Huang, Xing Li, Jun-Rong Jiang, Min Dong, Tian-Tian Wang, Dong-Hao Wu, Xiao-Kun Ma

    E15605 Background: Cholangiocarcinoma is a highly malignance with poor prognosis. To date,the prognostic factors remained unclear. Prior studies have demonstrated the prognostic value of pretreatment serum albumin to globulin ratio(AGR) in different types of cancer.This study was aimed to assess the predictive value of AGR on progression free survival (PFS) and overall survival(OS) in cholangiocarcinoma patients. Methods: We retrospectively studied 87 patients with cholangiocarcinoma who had documented pretreatment serum albumin and globulin levels from June 2003 to June 2007 in the Third Affiliated Hospital of Sun Yat-senUniversity.The primarystudyendpoint was OS.The predictive accuracy and discriminative ability of the AGR and other laboratoryindexes as well as tumor parameters for 1year survival after diagnosis were determined by ROC curves and the area under the ROC curve (AUC).The associations of preoperative AGR with clinicopathologic characteristics and prognosis were assessed. Univariate analysis and multivariate analyses using Cox regression models were performed to determine the independent prognostic value of AGR. Results: Univariate analysis by Cox regression reviewed that globulin, AGR,tumor size and TNM stage reached statistical significance when predicting OS with serum albumin presenting P > 0.05. Multivariate analyses showed that AGR was an independent prognostic factor for OS regardless of TNM stages and tumor size with serumglobulin failed to achieve positive results. However AGR did not present prognostic value for PFS. Next, the optimal cutoff point of AGR was determined to be 1.51 according to the ROC analysis. High AGR was significantly positively associated with ECOG and 1 year survival ratebut negatively correlated withage, alkaline phosphatase, gamma-glutamyl transpeptidase andtotal bilirubin . Moreover, Kaplan-Meier analysis showed that patients with low AGR displayed significantly poorer OS compared to the high AGR group. Conclusions: Preoperative AGR can act as an effective biomarker with easy accessibility for evaluating the prognosis of patients with cholangiocarcinoma. Patients with higher AGR levels may have better survival than those with lower AGR.

  • Myeloid deprived suppressor cell to mediate the prognostic value of neutrophil for advanced hepatocellular carcinoma patients.

    by Xing Li, Ai-Hua Lei, Yan-Fang Xing, Zhi-Huan Lin, Ying-Fen Hong, Qiang Xiao, Min Dong, Qu Lin, Xiang-Yuan Wu, Jie Zhou

    E15597 Background: Myeloid Deprived Suppressor Cell (MDSC) has been raised to be a novel target for multiple cancers. However, target agents on MDSC has not displayed promising efficacy. One of the critical reasons shall be less optimal patient selection. In the present study, we aimed to identify optimal advanced hepatocellular carcinoma (aHCC) patients for MDSC targeted therapy. Methods: In the present study, a series of 55 aHCC patients and 20 healthy donors were analyzed investigating frequencies of both monocytic MDSC (M-MDSC; defined as HLA-DRnegCD14posCD33posCD11bpos) and G-MDSC (defined as HLADRnegCD14negCD33posCD11bposCD15pos) in peripheral blood mononuclear cells (PBMC). Then, the association between MDSC and routing blood cell counts were analyzed to identify the possible predictors of MDSC level. Then, the prognostic value of the predictors was determined in retrospective database of 255 aHCC patients. Results: As a result, we found that G-MDSC level (median 5.55%, range 0.60-26.7%) was increased in HCC patients compared to healthy donors (median 1.55%, range 0.60-4.7%). M-MDSC level was also higher in a group (median 1.95%, range 0.006-13.7%) than the healthy control (median 0.55%, range 0.001-1.67%). Then the association of MDSC with routing blood cell counts was detected. And the neutrophils counts was positively associated with G-MDSC level (r2= 0.091, p = 0.011) and M-MDSC level (r2= 0.138, p = 0.002). Furthermore, univariate analysis by Cox regression revealed that neutrophils were associated with unfavorable overall survival (OS) (p = 0.000, HR 1.057, 95% CI 1.032-1.084). Then, neutrophils were integrated into cancer of the liver Italian program (CLIP) score system to determine its independence in prognostic value, since CLIP was the most accepted prognostic system for aHCC patients. The result showed that neutrophil count was a independent unfavorable prognostic factor for aHCC patients) (p = 0.000, HR 1.055, 95% CI 1.025-1.086). Conclusions: In summary, the present study indentified neutrophils counts was a predictor of MDSC level in aHCC patients. And, patients with higher neutrophils count level might be the optimal patient subgroup for MDSC targeted therapy.